Biophysical Reviews

, Volume 10, Issue 5, pp 1263–1282 | Cite as

Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention

  • Ruth NussinovEmail author
  • Mingzhen Zhang
  • Chung-Jung Tsai
  • Tsung-Jen Liao
  • David Fushman
  • Hyunbum Jang
Open Access


Autoinhibition is an effective mechanism that guards proteins against spurious activation. Despite its ubiquity, the distinct organizations of the autoinhibited states and their release mechanisms differ. Signaling is most responsive to the cell environment only if a small shift in the equilibrium is required to switch the system from an inactive (occluded) to an active (exposed) state. Ras signaling follows this paradigm. This underscores the challenge in pharmacological intervention to exploit and enhance autoinhibited states. Here, we review autoinhibition and release mechanisms at the membrane focusing on three representative Ras effectors, Raf protein kinase, PI3Kα lipid kinase, and NORE1A (RASSF5) tumor suppressor, and point to the ramifications to drug discovery. We further touch on Ras upstream and downstream signaling, Ras activation, and the Ras superfamily in this light, altogether providing a broad outlook of the principles and complexities of autoinhibition.


KRAS HRAS NRAS K-RAS4A K-RAS4B Drug Inhibitor Allosteric Activation 


Ras effectors play major roles in cell fate (Ahearn et al. 2011; Barnoud et al. 2017; Donninger et al. 2016; Iwasa et al. 2018; Sanchez-Sanz et al. 2016). Their affinities to Ras, signaling timescales, functions, and mechanisms vary (Herrmann et al. 1996; Jarvis 2011; Karasarides et al. 2001; Liao et al. 2016; Linnemann et al. 2002; Nussinov et al. 2016b; Nussinov et al. 2018c; Owonikoko and Khuri 2013; Pons-Tostivint et al. 2017; Rusanescu et al. 2001; Stephens et al. 2005; Vadas et al. 2011). Current observations suggest that all are autoinhibited at the membrane.

Below, we lay out the principles of autoinhibition and its release, focusing on Raf protein kinase, phosphatidylinositide-3-kinase α (PI3Kα) lipid kinase, and Ras association domain family 5 (RASSF5, a.k.a. NORE1A) tumor suppressor; however, our discussion is general. Cell signaling needs to be sensitive to the environment, and sensitivity is feasible only if the difference in the stabilities between the OFF and ON states is small, requiring only a small-scale shift in the equilibrium. The interactions between the target protein and its autoinhibiting segment, domain, or subunit display a continuum; if they are less stable, crystallography (or NMR) is unlikely to capture the autoinhibited conformation; if they are slightly more stable, it will (Huang et al. 2007). This principle clarifies autoinhibition and its release, and underscores the challenge facing pharmacology aiming to sustain autoinhibited states.

We selected Raf, PI3Kα, and NORE1A as representative Ras targets (Fig. 1) that have some mechanistic structural data and discuss their autoinhibition and its release to the extent that the data permit. Whereas even without the involvement of Ras, the release of the autoinhibition with subsequent kinase domain dimerization are sufficient for full activation of a Raf molecule, and active Ras increases the otherwise minor population of the active species, this is not the case for PI3Kα. In PI3Kα, release of the autoinhibition and Ras binding are two independent, additive components of full activation (Karasarides et al. 2001). To increase the population of the active Raf species, at least two elements are required: (i) spatial proximity of Ras molecules, via Ras nanoclustering (or dimerization/oligomerization) and (ii) high affinity to Ras. Neither is required for PI3Kα, where the release of the autoinhibition and the consequent increase in the population of the active species is via high affinity binding of a phosphorylated C-terminal motif of receptor tyrosine kinase (RTK) (Stephens et al. 2005; Vadas et al. 2011). NORE1A’s activation displays features common to Raf (Liao et al. 2016). However, in this case, being a tumor suppressor in the Hippo pathway, it is the high affinity of the Sav-RASSF-Hippo (SARAH) heterodimer of NORE1A and mammalian sterile 20-like kinase 1/2 (MST1/2) that shifts the equilibrium toward an active NORE1A species. Ras binding releases NORE1A autoinhibition. Active NORE1A binding to MST1/2 increases the population of active MST kinase domain dimers.
Fig. 1

Ras and its effectors. Cartoon representation of the crystal structures of a GppNHp-bound HRas interacting with the Ras binding domain (RBD) of Raf-1 (PBD code: 4G0N), b GppNHp-bound HRasG12V mutant interacting with the catalytic subunit of PI3Kγ (PBD code: 1HE8), and c GppNHp-bound HRas interacting with the Ras association (RA) domain of murine NORE1A (PBD code: 3DDC)

Figuring out the autoinhibition and activation mechanisms of Ras targets at the membrane may not directly suggest Ras pharmacology; however, it can help clarify what may or may not work. Below, our review is within this light.

Autoinhibition: variations on a theme

Autoinhibition and its release are common regulatory mechanisms, in solution, as for example in cyclic adenosine monophosphate (cAMP)- and cyclic guanosine monophosphate (c-GMP)-dependent protein kinases which are autoinhibited by interactions between their respective regulatory and catalytic domains (Francis et al. 2002), and in membrane-attached proteins, as in the neuronal membrane remodeling protein nervous wreck (NwK), which is autoinhibited by interactions between its membrane-binding Fes/Cip4 homology-Bin/Amphiphysin/Rvs167 (F-BAR) domain and its C-terminal Src homology 3 (SH3) domain (Stanishneva-Konovalova et al. 2016).

Autoinhibition is similarly common upstream and downstream Ras signaling cascades. Like all kinases, unbound epidermal growth factor receptors (EGFRs) are typically in the autoinhibited state with only 2 to 10% in the extended, active conformation (Schlessinger 2003). The EGFR tyrosine kinase domain is autoinhibited by intramolecular interactions between a short α-helix in its activation loop and the αC helix, which is shifted in active EGFRs, like Src family and cyclin-dependent kinases (CDKs) (Artim et al. 2012; Ferguson et al. 2003). In the extracellular domain of EGFR, the dimerization arms of subdomains II (cysteine-rich 1, CR-1) and IV (CR-2) interact, constraining subdomains I (leucine-rich 1, LR-1) and III (LR-2), preventing ligand binding (Schlessinger 2003). The high-affinity ligand binds to extended active state conformations, subdomain II dimerization arm is liberated, the equilibrium is shifted, relieving the autoinhibition and driving dimerization (Fig. 2a). Autoinhibition also regulates membrane-attached upstream Ras superfamily regulators (Cherfils and Zeghouf 2013). In guanine nucleotide exchange factors (GEFs), an active GTPase binds the allosteric site and mediates activation of an inactive molecule in the catalytic site, with a feed-forward loop flow. Son of Sevenless 1 (SOS1), which activates Ras, is one example (Fig. 2b) (Chardin et al. 1993; Cherfils and Chardin 1999; Gureasko et al. 2010; Lepri et al. 2011; Margarit et al. 2003; Rojas et al. 2011; Tartaglia et al. 2007; Vo et al. 2016). High affinity Ras-GTP binding at the allosteric site shifts the ensemble toward the active state, with large conformational changes (Boriack-Sjodin et al. 1998; Freedman et al. 2006; Pierre et al. 2011) that enable GDP exit and subsequent GTP binding (Liao et al. 2018). High affinity Ras-GTP binding is also the trigger for the population shift in KRas4B from an autoinhibited (GDP-bound) state, where the hypervariable region (HVR) loosely covers the active site (Fig. 2c), toward the active, open state (Chavan et al. 2015; Jang et al. 2015; Jang et al. 2016).
Fig. 2

Examples of autoinhibition. a Collapsed conformation of the extracellular domain retains EGFR in an inactive, autoinhibition state. The inactive EGFR monomer can form a symmetric dimer but remains in the inactive state. The autoinhibition is released when the EGF ligand binds to the extracellular domain, causing an extended conformation of the extracellular domain and resulting in an asymmetric assembly of the kinase domains. This shifts the population to the active EGFR dimer. b SOS1, a GEF for Ras, contains histone-like fold (HF), Dbl-homology (DH), and pleckstrin-homology (PH) domains at the N-terminal region, and REM, Cdc25, and C-terminal SH3 binding motif at the C-terminal catalytic region. Inactive SOS1 is autoinhibited by the DH and PH domains that hamper the REM allosteric site for Ras binding. The C-terminal tail also blocks the Cdc25 catalytic site for Ras binding. The SH3 domain of growth factor receptor bound protein-2 (GRB2) binds the proline-rich SOS1 C-terminal tail and recruits SOS1 to the cell membrane. Membrane interactions of the DH and PH domains release autoinhibition and Ras association. c Autoinhibitions of KRas4B-GDP in solution and at the membrane interaction. In the inactive autoinhibition state, the HVR covers the effector binding site, resulting in occlusion of the catalytic domain membrane orientation. The KRas4B structures were adopted from previous work (Jang et al. 2016)

Autoinhibition is similarly common among Ras superfamily effectors, such as p21-activated kinase 1 (PAK1). PAK1 autoinhibitory domain quenches the catalytic kinase domain. Cdc42 high-affinity interaction activates PAK1 by binding to the same region as the regulatory domain. Conformational rearrangements and autophosphorylation release the autoinhibition (Deacon et al. 2008; Tu and Wigler 1999).

The advantages of autoinhibition are clear: it guards against spurious activation, setting a concentration threshold. The low affinity of the regulatory part permits signaling sensitivity. However, this challenges structural determination of the autoinhibited state, as in the cases of Raf, PI3Kα by both N- and C-terminal SH2 domains (nSH2 and cSH2), RASSF5 (NORE1A), and Ras. But relatively, weak interactions enable higher affinity activators, if present at sufficiently high effective local concentrations, to shift the equilibrium in favor of an “open” active state, executing the cell’s adaptation to the environment.

Autoinhibition of Ras effectors

Raf kinase

The autoinhibited state

The absence of a crystal (or NMR) structure of Raf’s autoinhibited conformation suggests an ensemble of “closed” monomeric states with the N-terminal tail, Ras binding domain (RBD), cysteine-rich domain (CRD), and linker, with its Ser/Thr-rich segment, hindering kinase domain dimerization. (The RBD-CRD region is denoted conserved region 1 (CR1) and the Ser/Thr-rich region as CR2 (Fig. 3a) (Lavoie and Therrien 2015; Terrell and Morrison 2018)). Several observations support such autoinhibiting organization:
  1. (i).

    Removal of the N-terminal region dysregulates Raf’s kinase activity (Bruder et al. 1992; Fukui et al. 1987; Heidecker et al. 1990; Ishikawa et al. 1988; Ishikawa et al. 1986; Molders et al. 1985; Schultz et al. 1988; Stanton and Cooper 1987; Stanton et al. 1989);

  2. (ii).

    Overexpression of CR1 abolishes Raf’s catalytic activity (Chong and Guan 2003; Cutler et al. 1998; Tran and Frost 2003; Tran et al. 2005);

  3. (iii).

    B-Raf binding to active HRas abolishes the interaction of the N-terminal region with the kinase domain;

  4. (iv).

    Ser446 phosphorylation of B-Raf weakens the autoinhibition but S446A substitution increases it, suggesting that alanine strengthens the interaction;

  5. (v).

    Acidic substitutions at phosphorylation sites in the activation loop, Thr599 and Ser602 (Tran et al. 2005; Zhang and Guan 2000; Zhang and Guan 2001), and the oncogenic V600E mutation of B-Raf weaken the autoinhibition (Wan et al. 2004). These B-Raf activation loop residues in the kinase domain (Fig. 3b) (following the DFG motif (Kohler et al. 2016)) are analogous to Thr491 and Ser494 of Raf-1 (Fig. 3c) (Chong et al. 2001).

  6. (vi).

    Phosphorylations of Ser338 and Tyr341 (in Raf-1; aspartic acids in B-Raf) weaken the autoinhibition (Chong and Guan 2003; Tran and Frost 2003);

  7. (vii).

    B-Raf Ser446 (Ser338 in Raf-1) is constitutively phosphorylated in immortalized COS and PC12 cells (Mason et al. 1999; Tran et al. 2005). Further,

  8. (viii).

    Phosphorylation of Ser259 (Raf-1) or Ser365 (B-Raf) in the CR2 by protein kinase A (PKA) (Cook and McCormick 1993; Dhillon et al. 2002b; Lavoie and Therrien 2015; Wu et al. 1993) and Akt (Rommel et al. 1999; Zimmermann and Moelling 1999) (or large tumor suppressor 1 (LATS1) (Romano et al. 2014)) affects autoinhibition (Lavoie and Therrien 2015), and S259A of Raf-1 promotes activation (Dhillon et al. 2002b; Morrison et al. 1993).

Fig. 3

Structures of Raf kinase. a Domain structures of B-Raf and Raf-1. All Raf kinases share three conserved regions; CR1 involves the RBD and CRD, CR2 contains the Ser/Thr-rich region at the flexible linker, and CR3 is the kinase domain. For B-Raf, the 14-3-3 protein binds phosphorylated serine residues at Ser365 and Ser728 in CR2 and C-Terminal tail, respectively, and at Ser233, Ser259, and Ser621 for Raf-1. b Crystal structure of the kinase domain of B-Raf (PBD code: 4WO5). Phosphorylation at Ser446 weakens the autoinhibition, while S446A increases it. Acidic substitution and phosphorylation at Thr599 and Ser602 weaken the autoinhibition as well as the oncogenic mutation of V600E. c Crystal structure of the kinase domain of Raf-1 (PBD code: 3OMV). Phosphorylation at Ser338 and Tyr341, and acidic substitution and phosphorylation at Thr491 and Ser494 weaken the autoinhibition. Phosphorylated and mutated residues are marked red and green, respectively

Finally, the importance of the region in autoinhibition is also implied by other nearby substitutions that enhance Ras–Raf binding (Dhillon et al. 2002a; Light et al. 2002). In line with this, phosphorylated Ser259 of Raf-1 is recognized by 14–3-3 proteins (Michaud et al. 1995; Muslin et al. 1996; Rommel et al. 1996; Tzivion et al. 1998), which also bind phosphorylated Ser621 (Fig. 3a) (Michaud et al. 1995; Muslin et al. 1996; Rommel et al. 1996). Concomitant 14-3-3 binding at both sites may stabilize the interaction between the N-terminal segment and the kinase domain (Matallanas et al. 2011; Tzivion et al. 1998). Simultaneous binding at phosphorylated Ser233 of Raf-1 was also observed (Dumaz and Marais 2003; Molzan and Ottmann 2012).

The active state

Whereas structural data are unavailable for Raf’s autoinhibited state, some NMR and crystal structure data, coupled with modeling are available for the Ras-bound state (Fig. 1a). The high affinity (nanomolar range) binding of Raf’s RBD to active Ras recruits Raf to the plasma membrane (Chuang et al. 1994; Herrmann et al. 1995). The crystal structure of Ras with RBD is available (Fetics et al. 2015), as well as NMR structural data of CRD in solution (Mott et al. 1996). Abundant data point to Ras proteins anchorage via their prenylated HVR, and their spatial proximity—nanoclusters or dimers/oligomers—increases Raf’s effective local concentration, promoting the dimerization of Raf’s kinase domains and activation (Fig. 4). However, even though already early on CRD was established to interact with the membrane and stabilize the Ras–Raf interaction (Chuang et al. 1994), how it fits into Raf activation scenario and exactly what is its function have been unclear and challenging to address experimentally (Li et al. 2018a). Three recent modeling publications (Li et al. 2018a; Li et al. 2018b; Travers et al. 2018) aimed to elucidate its role. Isolated Raf-1 CRD can stably anchor to the membrane. This occurs via basic residues interjecting into the amphipathic membrane surface (right inset of Fig. 4). Explicit solvent molecular dynamics simulations suggest that in Raf-1 this “membrane insertion” loop region residues Lys144, Lys148, and Lys157 play a key role in the membrane attachment (Li et al. 2018a), which is supported by experimental mutational data of Arg143, Lys144, and Ly148 (Improta-Brears et al. 1999). Hydrophobic residues in the loop further enhance the membrane attachment. Modeling points to a high probability of the loop interacting with the membrane, particularly phosphatidylserine (Li et al. 2018a), consistent with experimental observations (Improta-Brears et al. 1999). Significantly, simulations of the KRas4B–Raf-1 RBD-CRD (left inset of Fig. 4) also suggest that the preferred conformation and orientation of the CRD resembles that favored by the CRD when modeled only with the membrane (Li et al. 2018a). In Raf-1, the linker between Raf RBD and CRD is short; only 6 residues. The short linker connecting CRD to the RBD confines its spatial location in the complex between the RBD and the membrane, with no detected interactions of CRD with the KRas4B catalytic domain. Whereas the HRas farnesyl group can interact with the Raf-1 CRD (Thapar et al. 2004), while the two palmitoyls retain the Ras anchorage in the membrane, this is not the case in KRas4B where the farnesyl remains anchored. Jointly, the membrane-anchored HVR and the CRD can diminish the fluctuations of the Ras–RBD complex at the membrane, which increases its affinity. The reduced fluctuations stabilize the Ras–Raf RBD interaction, which promotes Raf activation. The details of exactly how Ras orients at the membrane, e.g., α3/α4 or α4/α5, the angle with respect to the membrane normal, and whether these reflect Ras isoform-specific preferences, which is what we believe, are still controversial (Abankwa et al. 2010; Gorfe et al. 2007; Jang et al. 2016; Li and Buck 2017; Mazhab-Jafari et al. 2015); reviewed in the literature (Li et al. 2018a). However, key considerations are the populations, or residence times of the different organizations and the availability of Ras effector binding sites for the RBD interaction.
Fig. 4

Ras/Raf signaling pathway. Ras forms nanoclusters and promotes Raf dimerization in the Raf/MEK/ERK (MAPK) pathway. Active Raf dimer tigers cascade phosphorylation signals through MEK1/2 to ERK1/2, leading to cell proliferation. The left inset cartoon represents the organization of KRas4B–RBD-CRD of Raf-1 complex at the membrane. CRD reduces Ras–RBD fluctuations at the membrane, increasing Ras–RBD affinity. The right inset cartoon shows the membrane interaction of Raf-1 CRD with the highlighted key basic residues (blue sticks) and the insertion loop containing hydrophobic residues (white cartoon tube). Zn2+ coordination sites are highlighted by green sticks. The cartoons were depicted from previous simulations (Li et al. 2018a)

Considering the high flexibility of the system, multiple organizations of Ras–RBD-CRD at the membrane are possible. The cartoon (left inset of Fig. 4) depicts those of KRas4B–Raf-1 which we observed to be among the most favored (Li et al. 2018a). In these orientations, the effector binding site of Ras faces away from the membrane surface allowing the RBD to interact with the Ras catalytic domain and the CRD to interact with the membrane. Ras is anchored in the membrane through its prenylated HVR. Even though the Ras–RBD interaction is of high affinity in solution, simulations indicate that at the membrane the fluctuations are significant. The constrained positioning of the CRD, contacting the membrane through the basic “insertion loop” and further supported by hydrophobic residues, and restricted by the short linker, restrains the fluctuations and stabilizes the Ras–RBD interaction. The observation that this orientation resembles that populated by CRD in the absence of the Ras–RBD lends support to this organization. Notably, CRD can recruit Raf-1 to the membrane even in the absence of Ras; however, by quenching the KRas4B–Raf-1 RBD fluctuations, CRD stabilizes the interaction, which increases the population of the active Raf species and thus signaling.

The activation mechanism

Even though the Ras–Raf link in mitogen-activated protein kinase (MAPK) has been known for decades, exactly how Ras activates Raf has been puzzling. Over the last few years, the community focused on the kinase domain dimer and its structure with the aim of unraveling the mechanism of the autophosphorylation, why and how resistance can defeat Raf inhibitors interacting with the kinase domains and overcoming the dimerization requirement, and broadly drug discovery (Freeman et al. 2013; Hatzivassiliou et al. 2010; Hu et al. 2013; Jambrina et al. 2014; Jambrina et al. 2016; Lavoie and Therrien 2015; Lavoie et al. 2013; Poulikakos et al. 2010; Rajakulendran et al. 2009; Thevakumaran et al. 2015; Zhang and Guan 2000; Zhang et al. 2015). However, much less was revealed about activation scenarios at the membrane. Possible reasons for this include the challenging presence of the long linker (~ 180 residues in B-Raf; ~ 170 residues in Raf-1) between CRD and the kinase domain (Fig. 3a), and the attachment to the membrane. In addition, the likely relatively weak interaction between the regulatory N-terminal region and the kinase domain may also be unyielding to experimental structural determination. Nonetheless, data have accumulated providing some insight into the inactive autoinhibited state, and thus the activation mechanism (Fig. 4).

In drawing a possible scheme (that awaits testing), we consider the high affinity of the Ras–RBD interaction: the residues whose phosphorylation abolishes the autoinhibition, data related to the consequences of alanine substitution, the suggested binding of the 14-3-3 protein to two phosphorylated sites as described above (Dumaz and Marais 2003; Lavoie and Therrien 2015; Molzan and Ottmann 2012; Tran et al. 2005), and our expectation that the inhibitory N-terminal is not tightly bound to the kinase domain. Rather than a hierarchical step-by-step activation process, we favor an ensemble view of the mechanism. The fundamentals of this concept, as well as its utilization to explain a broad range of observations have already been discussed (Boehr et al. 2009; del Sol et al. 2009; Kumar et al. 2000; Liu and Nussinov 2016; Liu and Nussinov 2017; Ma et al. 1999; Nussinov 2016; Nussinov et al. 2011; Nussinov et al. 2013c; Nussinov and Wolynes 2014; Tsai et al. 2009; Tsai et al. 1999a; Tsai et al. 1999b; Tsai and Nussinov 2014b; Wei et al. 2016). Raf molecules exist in an ensemble of conformations which includes all autoinhibited (inactive) species and the active state; however, the distribution of the ensemble depends on the conditions; that is, whether the cell is in a resting state, or stimulated/oncogenic. In the absence of an active, GTP-bound membrane-anchored Ras molecule, wild type Raf largely populates an autoinhibited state (Fig. 4), with a minor component of the active, “open” state. In the autoinhibited state, those segments pointed out by mutational and phosphorylation data may interact with the kinase domain. That this interaction may not be sufficiently stable is also suggested by the dual 14-3-3 interaction. In the presence of active Ras (and other cell factors possibly interacting with 14-3-3, as well as dephosphorylation of these sites, e.g., by protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1), (Abraham et al. 2000; Dhillon et al. 2002a; Jaumot and Hancock 2001; Lavoie and Therrien 2015; Ory et al. 2003)), the equilibrium shifts toward the uninhibited “open” state. The tight interaction with Ras is expected to alter the distribution of the ensemble, favoring the released intramolecular interactions with the kinase domain. This would explain why Raf evolved this high-affinity interaction. Phosphorylation events further contribute to the shift of the ensemble toward the active state (Nussinov et al. 2012). We note that such an ensemble view does not favor a description where an interaction actively “opens” Raf; instead, it advocates preexistence of states whose relative populations change with cell events, such as phosphorylation (or dephosphosphorylation), proximity of active Ras molecules, etc. This view is based on fundamental physicochemical principles. Macromolecules are not solid rocks; they are flexible, visiting multiple possible conformations (Nussinov and Wolynes 2014). Exactly which N-terminal and kinase domain regions interact, and whether these overlap the interaction with Ras, awaits modeling and data, such as NMR-detected residue-specific chemical shift perturbations, and high-resolution cryo-EM electron density maps. We believe that such data will point to the presence of several possible states.

Insight into drug discovery

Is blocking the release of the autoinhibition a productive strategy in drug discovery? Despite the absence of direct structural data of the autoinhibited state, the flexibility and the related relatively weak affinity of the intramolecular N-terminal region-kinase domain interaction underscore the challenge in targeting it. In agreement with these considerations, recently, the Therrien team successfully obtained Raf inhibitors that shift the equilibrium toward a disrupted autoinhibited state (Jin et al. 2017). Introduction of the inhibitor resulted in interruption of the presumably unstable intramolecular interactions between the N-terminal regulatory region and the kinase domain, independently of Ras state. Thus, to effectively disrupt the autoinhibitory interactions, high-binding affinity would be required, resembling Ras’ mode of action. A compound that would stabilize the autoinhibited state would be very difficult to attain.

PI3Kα lipid kinase

There are two independent components in PI3Kα activation

The regulation of PI3Kα also involves autoinhibition; however, the scenario at the membrane differs (Nakhaeizadeh et al. 2016). PI3Kα produces phosphatidylinositol (3,4,5)-trisphosphate (PIP3) from phosphatidylinositol 4,5-bisphosphate (PIP2), a critical signaling molecule that stimulates the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, which regulates cell growth and survival, cytoskeleton reorganization, and metabolism (Castellano and Downward 2011). PI3Kα consists of regulatory (p85α) and catalytic (p110α) subunits (Fig. 5a). The catalytic subunit contains five domains: the adaptor binding domain (ABD) that binds p85, the RBD, the C2 membrane-binding domain, the helical domain, and the catalytic kinase domain. The regulatory subunit consists of two SH2 domains (nSH2 and cSH2) separated by an intervening coiled-coiled domain (iSH2) (Nussinov et al. 2017b; Nussinov et al. 2018d; Zhang et al. 2017). The interactions of these SH2 domains with p110 result in covering PI3Kα active site (Fig. 5b), hindering the binding of the PIP2 substrate. PI3Kα becomes fully activated by binding to an active, GTP-bound Ras, and to phosphorylated C-terminal motifs (pYXXM) of RTKs, such as EGFR (or an associated protein, e.g., insulin receptor substrate 1 (IRS-1) (Backer et al. 1992)). The motifs of the RTK molecules interact with the nSH2 and cSH2 domains (Fig. 5c). The high-affinity binding of the phosphorylated C-terminal RTK motifs releases the autoinhibitory interactions primarily of nSH2, but also of cSH2 with the catalytic subunit, resulting in exposed active site (Nussinov et al. 2015a; Nussinov et al. 2016a; Nussinov et al. 2017b). The release of the autoinhibitory nSH2 domain allosterically helps PI3Kα activation. RBD’s binding to active Ras contributes by recruiting PI3Kα to the membrane and to allosteric activation of the kinase domain. Both events, binding the pYXXM motifs and Ras, increase the accessibility of PI3Kα to the PIP2 substrate at the membrane (Nussinov et al. 2016a).
Fig. 5

Domain structure of PI3Kα. a PI3Kα is composed of p110α catalytic and p85α regulatory subunits. While the structure of the p110α subunit has been determined, no structure is currently available for the N-terminal region of the regulatory subunit (SH3 and BH domains, denoted as white cylinder). b Modeled structure of PI3Kα, which is constructed from the crystal structure (PDB code: 4OVV), represents an autoinhibition structure. The interactions of the nSH2 and cSH2 domains of p85α with the catalytic p110α subunit impede PI3Kα activation. c Phosphorylated pYXXM motif (denoted as pY) of RTK liberates the nSH2 and cSH2 domains from the catalytic subunit, removing autoinhibition in the catalytic subunit and thus exposing the active site

The mechanisms of oncogenic mutations validate the two independent components in PI3Kα activation mechanism. Autoinhibition can be relieved by the E542K and E453K mutations in the helical and C2 domains, respectively. These mutations replace the stabilizing salt-bridge interactions of the nSH2 domain with the catalytic subunit by charge repulsion (Burke et al. 2012; Gabelli et al. 2014; Mandelker et al. 2009). N345K is another mutation that disrupts favorable inhibitory wild-type interaction. This mutation is at the iSH2-C2 interface in the C2 domain. The weakened interaction leads to loss of structural coupling to the nSH2 domain, loosening its autoinhibition (Gabelli et al. 2014), and to more favorable membrane binding, as indicated by an increased hydrogen/deuterium exchange level (Burke et al. 2012). Membrane binding is allosterically coupled to the ABD-RBD linker far away (Ma et al. 2011). Further, the R88Q mutation in the ABD abolishes the hydrogen bonding of the arginine with the kinase domain (Zhao and Vogt 2008a). The resulting higher catalytic activity is consistent with another mutation involving a deletion of the ABD (Zhao and Vogt 2010), pointing to the ABD as part of the nSH2 autoinhibition via association with the catalytic subunit. On the other hand, the allosteric stimulation by active Ras binding to p110 RBD (Gupta et al. 2007; Kodaki et al. 1994) resembles conformational changes in the p110 C-lobe at the membrane interface induced by PI3Kα “hot spot” (H1047R) mutation in the kinase domain of p110 (Mandelker et al. 2009; Zhao and Vogt 2008b). The resulting increased membrane binding and accessibility to PIP2 makes the H1047R mutational variant independent of Ras-GTP (Zhao and Vogt 2008b). Thus, whether in Raf or in PI3Kα, oncogenic mutations can inform about activation mechanisms.

PI3Kα activation scenario at the membrane

Thus, unlike Raf whose activation at the membrane involves a shift of the ensemble toward the more stable Ras–Raf interaction (Fig. 4), PI3Kα activation at the membrane involves two independent events: release of the autoinhibition by RTK’s phosphorylated C-terminal motif and Ras allosteric activation (Fig. 5c). Both are required for full activation. Ras isoforms do not display high affinity to PI3Kγ, which is much lower than PI3Kα, but is sufficient for interactions of two proteins (Pacold et al. 2000; Rodriguez-Viciana et al. 1996). This micromolar affinity interaction with Ras already indicates that its role is unlikely to be mediated via a population shift of the autoinhibited state. At the same time, the PI3Kα substrate is anchored at the membrane, indicating that the PI3Kα active site must be at the membrane and oriented for PIP2 to dock into it. Like Raf, where the autoinhibitory interactions are relatively weak, in PI3Kα, the interactions of the SH2 domains, especially cSH2, with the kinase domain are also unstable; however, these are released via the involvement of the RTK motif. Further in contrast to Raf, even though PI3K is a dimer, it essentially acts as a monomeric unit. As such it does not require Ras nanoclustering (or dimerization). Finally, the two-component activation explains why even without Ras, PI3Kα can be activated—albeit not fully.

The dissociation constant, KD, for the Ras–PI3K complex is higher than that for the Ras–Raf RBD (Herrmann et al. 1995; Sydor et al. 1998) and the Ras–RBD of Ras-Ral guanine nucleotide dissociation stimulator (RalGDS) complexes (Herrmann et al. 1996), underscoring the role of calmodulin (CaM) in PI3K activation, and the different mechanisms of activation at the membrane. Thus, as we discuss below, even though both effectors deploy autoinhibition as a key component in their regulation, their detailed mechanisms differ, as do their chemical reactions. PI3Kα lipid kinase catalytic activation is at the membrane, which is not the case for Raf’s protein kinase domains. The exposed active site of the lipid kinase domain needs to be productively oriented toward the membrane. The PIP2 substrate is membrane-anchored and phosphorylated at the active site. The solvent-miscible ATP is far away.

PI3Kα catalysis

Raf is a protein kinase. Its substrates are proteins. By contrast, PI3Kα phosphorylates lipids. Even though there is some similarity in their active sites—both bind ATP—the different types of substrates and environments evolved distinctiveness. PI3Kα catalysis is regulated by membrane binding and the population of effective phosphate transfer transition complexes (Burke et al. 2012; Gabelli et al. 2014; Nussinov et al. 2017b; Zhao and Vogt 2008a). Experimental data indicate that both are required for full activity, and that they are structurally coupled. This can be seen by the Km, the PIP2 concentration at which PI3Kα is at half of its maximal catalytic rate (kcat). The Michaelis-Menten kinetic efficiency (kcat/Km) directly measures the enzyme activity. Here, the dissociation of nSH2 from p110α enables the effective formation of phosphate transfer transition complex, analogous to an increase of kcat. Experimental data indicate that both membrane binding capability and effective formation of the phosphate transfer transition complex are required for a fully active PI3Kα (Nussinov et al. 2015a). PI3Kα activity reflects the efficiency of the individual steps, ATP and PIP2 (cofactor and substrate, respectively) binding, phosphoryl transfer, and dissociation of the products. If we do not consider ATP binding and ADP and PIP3 dissociation steps, activation can be evaluated by kcat/Km based on a two-step reaction (Miled et al. 2007). PIP2 accessibility to the PI3Kα active site is connected to its ability to bind the membrane, as indicated in the Km. By contrast, the release of the autoinhibition by the dissociation of the nSH2 from the catalytic subunit effectively permits the formation of phosphate transfer transition complex, correlates with an increase of kcat.

Insight into drug discovery

To date, there are no PI3Kα drugs in the clinics. Exploiting the autoinhibited states may be challenging. However, currently, we are exploring strategies to obstruct the kinase reaching a catalytically-productive state involving the ATP and the lipid substrate at the membrane, a scenario differing from that of Raf.

NORE1A tumor suppressor

NORE1A: autoinhibition and its release

NORE1A (RASSF5) interacts with active Ras and activates the MST1/2 (Avruch et al. 2009; Avruch et al. 2012; Donninger et al. 2016; Liao et al. 2016; Nussinov et al. 2017a; Richter et al. 2009). The signal propagates through the Hippo-pathway phosphorylation cascade, leading to phosphorylation of Yes-associated protein 1 (YAP1), which targets it for degradation (Fig. 6). Overexpressed YAP1 promotes cell proliferation (Fallahi et al. 2016). NORE1A, Raf, and PI3K all share the same binding site on Ras. However, different from these other Ras effectors, NORE1A is not a kinase. In its inactive state, NORE1A is autoinhibited by its Ras association (RA) domain interacting with its SARAH domain. The two domains are connected by a flexible hinge. The interaction is weak, and fluctuating; thus, no experimental structure. When activated, the SARAH domain swings to dissociate from the RA domain and heterodimerize with the MST1/2 SARAH domain. In the MST inactive state, the kinase domain is autoinhibited by its SARAH domain; in the open state, the SARAH is dissociated from the kinase domain. The high-affinity SARAH heterodimer (of the NORE1A and the MST1/2) interaction shifts the equilibrium toward the active open MST1/2 state, enabling the homodimerization of the kinase domains, and the trans-autophosphorylation. Even though MST1/2 SARAH homodimerization can take place, its affinity is lower than that of the hetero-SARAH dimer (Hwang et al. 2014; Makbul et al. 2013). Thus, mechanistically, NORE1A plus MST1/2 resemble Raf. As in Raf, Ras dimer (or nanocluster) can associate with two NORE1A molecules, which heterodimerize with two MST’s SARAH domains (Fig. 6). However, the functional outcome differs: Raf promotes proliferation whereas NORE1A suppresses it. MST1/2 requires NORE1A’s help since it does not have a Ras-binding domain. NORE1A is essentially an adaptor bridging Ras and MST (Liao et al. 2016). The Ras interaction is essential, since it brings the two MST1/2 kinase domains into spatial proximity, promoting MST1/2 activation (Liao et al. 2017; Stieglitz et al. 2008). In its absence, the effective local concentration may be too low. NORE1A binds to Ras through its RA domain with a micromolar affinity. Thus, whereas the tight interaction between Raf’s RBD and Ras drives the equilibrium toward Raf’s open active state, for NORE1A, the high-affinity interaction driving the active MST1/2 kinase state is that between the two SARAH domains. Its C1 domain anchors into the membrane. Its exact role in the mechanism of NORE1A activation is still unclear, although it is possible that is resembles that of Raf’s CRD. Through the NORE1A–MST SARAH domain heterodimerization, the MST kinase domain links to active Ras, inducing the MST kinase domain dimerization and phosphorylation just like Raf’s kinase domain (Liao et al. 2016).
Fig. 6

RASSF5 (NORE1A) and Hippo pathway. RASSF5 is an adaptor protein and composed of the cysteine-rich C1 (not shown), RA, and the SARAH domains. An isolated RASSF5 is autoinhibited by its RA domain interacting with its SARAH domain. In the presence of Hippo signal, MST1/2 binds to salvador homolog 1 (SAV1) scaffolding protein and is phosphorylated by upstream signal. SAV1 contains two consecutive Trp-rich WW domain and the SARAH domain. The interaction of SAV1–MST1/2 promotes phosphorylation of MOB kinase activator 1 (MOB1) and LATS1/2. A phosphorylation cascade to YAP1 causes degradation of p-YAP1 and thus suppressing tumor. In the presence of proximal Ras nanocluster, two RASSF5 proteins bind a Ras dimer, liberating their SARAHs to recruit MST1/2 SARAH, facilitating MST1/2 dimerization through their kinase domains. Cross phosphorylated MST1/2 by each kinase domain promotes phosphorylation of MOB1, LATS1/2, and YAP1, resulting in its degradation. In the absence of Hippo signal, the unphosphorylated YAP1 can be translocated into the nucleus and bind to the transcription factor TEAD. This leads to cell proliferation as the MAPK pathway. Without proximal Ras nanocluster, RASSF5 in complex with monomeric Ras does not promote MST1/2 dimerization and phosphorylation, increasing population of unphosphorylated YAP1

The micromolar range RA–Ras interaction is insufficient to drive the equilibrium in the way that the nanomolar Raf RBD–Ras does. However, the high affinity SARAH NORE1A–MST1/2 heterodomain interaction can, shifting the equilibrium toward MST1/2 kinase domain homodimerization and activation. Thus, even though there is a general mechanistic similarity between NORE1A + MST1/2 and Raf, and the release of the autoinhibition through a shift of the ensemble is caused by a high-affinity interaction, the details differ: whereas in Raf the interaction with Ras is the cause, in NORE1A the cause is the SARAH domain interaction with MST1/2. Either way, in both cases, the outcome is the dimerization and activation of the kinase domains.

Insight into drug discovery

In the case of RASSF5 tumor suppressor, pharmacological efforts should not be aimed at promoting the autoinhibition but abolishing it.

Additional factors in activation at the membrane


Mutations and additional cell-specific factors can also play a role in effector activation. These may relate to, e.g., expression, cell-to-cell variation in gene expression and the propagation of such variation (Martins et al. 2017), plasma membrane microdomain environment (Goldfinger and Michael 2017; Lommerse et al. 2005; Zhang et al. 2018a), membrane-associated scaffolding proteins (Michael et al. 2016), membrane delivery (Weise et al. 2011), and ubiquitination/deubiquitination (Simicek et al. 2013; Wan et al. 2017) which may affect HVR-membrane attachment, thus Raf versus PI3K signaling, as well as sumoylation (Choi et al. 2018). Mutations may also differentially affect Ras target activation (Hamad et al. 2002; Nussinov et al. 2015b; Rodriguez-Viciana et al. 2004; Rodriguez-Viciana et al. 1997; Vandal et al. 2014). KRasT35S and KRasD38E activate MAPK signaling, but do not bind RalGDS or PI3K; however, KRasG12V/T35S or KRasG12V/D38E mutants are associated with higher cancer occurrence than KRasG12V and KRasG12V/E37G. KRasG12V/E37G prefers RA domain-containing proteins such as NORE1A more than other mutants (Chang et al. 2014; Schubbert et al. 2007; Vandal et al. 2014). Further, KRasG12V/Y40C coexpressed with B-RafV600E, appears to be less oncogenic than with B-RafV600E expression alone. Expression of B-RafV600E and KRasG12V/D38E resulted in smaller tumors than of only B-RafV600E. KRasT35S, but not KRasD38E, interacts weakly with RalGDS and Ral GDP dissociation stimulator-like (RGL) (Rodriguez-Viciana et al. 2004; Rodriguez-Viciana et al. 1997). Preferred effector interaction may reflect shifts in the conformational ensemble by specific mutations, or combinations (Nussinov et al. 2013b; Nussinov and Tsai 2015; Tsai and Nussinov 2014a; Tsai and Nussinov 2014b). Below, we briefly focus on two factors, CaM and scaffolding proteins.


Oncogenic Ras can bind PI3Kα’s RBD and recruit the kinase to the membrane, but it is unable to fully activate it. In the absence of the signal-activated phosphorylated RTK’s C-terminal motif, the autoinhibition is still in place. Based on experimental data (Chaudhuri et al. 2016; Joyal et al. 1997; Joyal et al. 1996; Liao et al. 2006), we suggested that Ca2+-CaM, especially when phosphorylated at Tyr99, can complement KRas (KRas4A and KRas4B) by binding to the n/cSH2 domains, replacing the missing RTK signal (Fig. 7) (Nussinov et al. 2015a; Nussinov et al. 2017b; Wang et al. 2018; Zhang et al. 2017; Zhang et al. 2018b). CaM’s negatively-charged linker binds tightly to KRas’ highly positively charged HVR (Abraham et al. 2009; Jang et al. 2017), and its hydrophobic N-lobe pocket offers a docking site to the KRas farnesyl group (Banerjee et al. 2016; Jang et al. 2017); but is unable to stably bind the neutral HVRs of HRas and NRas (Alvarez-Moya et al. 2011; Villalonga et al. 2001). This can explain CaM’s role in KRAS-driven cancers (Nussinov et al. 2017b), in line with genetically-engineered mouse models showing that oncogenic KRas can induce senescence or proliferation and differentiation (Xu et al. 2014), but is unable to induce full PI3Kα activation. Our structural model of the PI3Kα heterodimer (Vadas et al. 2011; Vanhaesebroeck et al. 2001) includes the p110α catalytic subunit and the three p85α n/i/cSH2 domains (Fig. 5b), ATP in the p110 cleft between the N- and C-lobes, the two phosphorylated RTK peptides binding the n/cSH2 (Nussinov et al. 2015a), and PIP2 at the p110 active site. Different proteins can fulfill CaM’s role in oncogenic HRas and NRas in full activation of PI3Kα (Nussinov et al. 2018d), with scaffolding protein, IQ motif containing GTPase activating protein 1 (IQGAP1) being one possibility (Hedman et al. 2015; Ren et al. 2008). Direct physical interaction between Raf kinase and oncogenic Ras promotes Raf side-to-side dimerization (Fig. 4) (Rajakulendran et al. 2009) and MAPK signaling (Crews and Erikson 1993); however, both oncogenic KRas4B and CaM are involved in PI3Kα and Akt activation (Fig. 7), with CaM directly activating PI3Kα (Joyal et al. 1997; Liao et al. 2006), as well as Akt (Agamasu et al. 2015; Agamasu et al. 2017).
Fig. 7

RTK-independent PI3Kα/Akt/mTOR pathway leading to cell growth. In adenocarcinoma of KRAS-driven cancer, CaM specifically recruits active KRas4B from the membrane to PI3Kα and activates it. The binding site of CaM with phosphorylation at Tyr99 (pY99-CaM) acts as the RTK’s pYXXM motif, substituting for the missing RTK signal. Interactions of CaM with n/cSH2 domains of p85α regulatory subunit remove the autoinhibition on the p110α catalytic subunit. CaM also removes the autoinhibition of Akt, releasing the PH domain from its kinase domain, and recruits Akt to the plasma membrane promoting the PH domain to bind PIP3. PI3Kα phosphorylates PIP2 to produce PIP3 that recruits both PDK and Akt to the plasma membrane


PIP3 is sequentially generated by phosphatidylinositol 4-kinase IIIα (PI4KIIIα, a.k.a. PI4KA), phosphatidylinositol 4-phosphate 5-kinase Iα (PIPKIα, a.k.a. PIP5KIα), and PI3Kα lipid kinases; all scaffolded by IQGAP1 (Fig. 8a). IQGAP1 is a 190-kDa protein involved in regulating processes such as organization of the actin cytoskeleton, transcription, and cellular adhesion to regulating the cell cycle. It can interact with over 160 proteins, including PI3K, CaM, Cdc42, and Rac (Choi and Anderson 2016; Choi et al. 2016; Hedman et al. 2015; Ozdemir et al. 2018; Smith et al. 2015) and mediates actin-binding. The first step, the conversion of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P), the precursor of PIP2 and PIP3, is catalyzed by the PI4KIIIα complex (Fig. 8b). Truncation mutants indicated that PIPKIα interacts with the IQ domain, while the p85 subunit of PI3Kα interacts with both the WW and IQ domains of IQGAP1 (Choi et al. 2016). Scaffolding these kinases into functional proximity generates PIP2 and subsequently PIP3, which then signals to phosphoinositide-dependent protein kinase 1 (PDK1) and Akt, that are also in the complex. Blocking the interaction of IQGAP1 with PIPKIα or PI3K inhibits generation of PIP3 and signaling. The four IQ motifs of IQGAP1 can interact with apo- or holo- CaM (Atcheson et al. 2011; Li and Sacks 2003; White et al. 2009). IQGAP1’s WW domain interacts with the SH2 domains and may thus substitute for CaM in oncogenic Ras activation (Choi et al. 2016). IQGAP1 lacks a membrane-binding domain. It may be autoinhibited in several sites. For example, Cdc42 binding to the Ex-domain of GTPase binding domain (GRD) of IQGAP2 (GRD2) releases the Ex-domain at the C-terminal region of GRD2, relieving the autoinhibition thus facilitating IQGAP2 dimerization. Cdc42 binding promotes allosteric conformational changes in the RasGAP site, resulting in a binding site for the second Cdc42 in the RasGAP site (Ozdemir et al. 2018).
Fig. 8

Domain structure of IQGAP1 and its scaffolding lipid kinases. a IQGAP1 is a large scaffolding protein and contains multi-domains, including calponin-homology domain (CHD), IQ repeats, polyproline binding region (WW), four IQ motifs (IQ), Ras GTPase-activating protein-related domain (GRD), and RasGAP C-terminus (RGCT). b IQGAP1 is a key regulator of phosphoinositide signaling, scaffolding various lipid kinases at the nearby plasma membrane. The lipid kinase PI4KIIIα converts PI → PI4P, PIPKIα converts PI4P → PIP2, and PI3Kα converts PIP2 → PIP3 at the plasma membrane. The tumor suppressor, phosphatase, and tensin homolog (PTEN) can reverse the PIP3 production

Raf (along with its mitogen-activated protein kinase kinase (MEK) substrate and the subsequent extracellular signal-regulated kinase (ERK) in the MAPK pathway) can also be scaffolded by IQGAP1; however, their major scaffolding protein is kinase suppressor of Ras (KSR). Raf family pseudokinases KSR1 and KSR2 can support the interaction of Raf isoforms with MEK. Unlike Raf, KSR lacks a Ras-binding domain; however, its dimerization with Raf stimulates Raf’s catalysis (Lavoie et al. 2018). As a peudokinase resembling Raf, KSR is also autoinhibited with the inhibition relieved by Ser406 dephosphorylation, 14-3-3 release and membrane attachment (Lavoie and Therrien 2015).

In addition to increasing the effective local concentration, enhancing, and stabilizing molecular adjacency, allosteric actions in scaffolding proteins are also expected to promote catalytic activity (Nussinov et al. 2013a), including in IQGAP1–lipid kinases interaction, and the KSR. Members of the galectin family can scaffold Ras isoforms (Rotblat et al. 2010) and have also been proposed as cancer targets (Rabinovich 2005). However, their detailed actions are unclear.


Activation of Raf, PI3Kα, and NORE1A involves release of autoinhibition at the membrane; however, the distinct mechanisms differ. Activation of Raf kinase domains requires dimerization, which necessitates their spatial proximity, along with the high affinity Ras–Raf interaction which drives the shift in the population from the inactive to the active, “open” Raf state (Fig. 4). By contrast, PI3Kα kinase domain is primarily activated by the release of the autoinhibition by the high-affinity binding of the phosphorylated RTK motif, with activation assisted by active Ras (Fig. 5c). Raf is a protein kinase; PI3Kα is a lipid kinase. Raf is activated by autophosphorylation, and its substrate is MEK; by contrast, PI3Kα’s substrate, PIP2, is a membrane-anchored lipid, which has been synthesized by sequential catalytic actions by lipid kinases. Even though PI3Kα is a dimer, p85α is a regulatory subunit. In the cell, it mostly keeps the p110 catalytic kinase subunit in the inactive autoinhibited state. Through release of the autoinhibition of its SH2 domains, it triggers activation. The lower affinity of its RBD to Ras suggests that as long as Ras predominantly exists as dimers or nanoclusters, Raf signaling will go through (Nussinov et al. 2018b). In the cell cycle, Raf’s activation and MAPK signaling precede PI3Kα/Akt, (Nussinov et al. 2018a): MAPK works in the first phase of the G1 stage; PI3Kα/Akt in the second (Nussinov et al. 2016c; Nussinov et al. 2015b). Both pathways are required to go through the checkpoint to proceed to the Synthesis, S stage. NORE1A’s scenario resembles Raf’s; except that the release of the inhibition does not emerge from the micromolar Ras binding, but from SARAH domain heterodimerization with MST1/2, with the ultimate activation being that of the MST1/2, through its kinase domains dimerization, mediated by NORE1A (Fig. 6). If Ras expression is sufficiently high, it can form dimers (or nanoclusters). These, coupled with Raf’s high affinity, boost Raf’s activation and initiate the MAPK signaling cascade. PI3Kα activation does not require nanoclustering. However, it requires proximity to RTK (possibly accomplished by sharing membrane lipid rafts) to directly release its autoinhibition, via the c/n/SH2 domains, and shift the equilibrium.

It has been suggested that proteins regulated by autoinhibitory domains can be promising targets for allosteric drugs that stabilize the native, autoinhibited fold (Peterson and Golemis 2004). Successful examples that we could find are imatinib (Gleevec, STI-571) and wiskostatin. The similarity between the conformation of the activation loop in the imatinib-Abl structure and the substrate-binding mode suggested that imatinib bound to a native autoinhibited conformation of Abl. The GTPase binding domain (GBD) of Neural Wiskott-Aldrich syndrome protein (N-WASP) interacts with its C-terminus, autoinhibiting the activation of the Arp2/3 complex (Panchal et al. 2003). Binding of Cdc42 to the GBD relieves this autoinhibition (Abdul-Manan et al. 1999; Kim et al. 2000). Two inhibitors of N-WASP (Peterson et al. 2004), 187-1 and wiskostatin, were identified. The 187-1 inhibitor stabilizes the autoinhibitory interaction of N-WASP against activation by Cdc42. The solution structure of wiskostatin bound to the WASP (Peterson et al. 2004) suggested that wiskostatin stabilizes the autoinhibited fold of the GBD. The isolated GBD was disordered in solution. Wiskostatin induced folding of the GBD into the autoinhibited conformation, suggesting that it stabilized the native autoinhibited fold of WASP (Peterson and Golemis 2004). Nonetheless, in the case of Ras effectors discussed here, with a priori loose interaction, retaining the autoinhibition of Raf will be challenging; as is also the case for PI3Kα.


Compliance with ethical standards


This project has been funded in whole or in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E. This research was supported [in part] by the Intramural Research Program of NIH, Frederick National Lab, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

Conflict of interest

Ruth Nussinov declares that she has no conflict of interest. Mingzhen Zhang declares that he has no conflict of interest. Chung-Jung Tsai declares that he has no conflict of interest. Tsung-Jen Liao declares that he has no conflict of interest. David Fushman declares that he has no conflict of interest. Hyunbum Jang declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. Abankwa D, Gorfe AA, Inder K, Hancock JF (2010) Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A 107:1130–1135. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, Siminovitch KA, Rosen MK (1999) Structure of Cdc42 in complex with the GTPase-binding domain of the ‘Wiskott-Aldrich syndrome’ protein. Nature 399:379–383. CrossRefPubMedGoogle Scholar
  3. Abraham D et al (2000) Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275:22300–22304. CrossRefPubMedGoogle Scholar
  4. Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V (2009) The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry 48:7575–7583. CrossRefPubMedPubMedCentralGoogle Scholar
  5. Agamasu C, Ghanam RH, Saad JS (2015) Structural and biophysical characterization of the interactions between calmodulin and the pleckstrin homology domain of Akt. J Biol Chem 290:27403–27413. CrossRefPubMedPubMedCentralGoogle Scholar
  6. Agamasu C, Ghanam RH, Xu F, Sun Y, Chen Y, Saad JS (2017) The interplay between calmodulin and membrane interactions with the pleckstrin homology domain of Akt. J Biol Chem 292:251–263. CrossRefPubMedGoogle Scholar
  7. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR (2011) Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 13:39–51. CrossRefPubMedGoogle Scholar
  8. Alvarez-Moya B, Barcelo C, Tebar F, Jaumot M, Agell N (2011) CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators. Small GTPases 2:99–103. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Artim SC, Mendrola JM, Lemmon MA (2012) Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem J 448:213–220. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Atcheson E, Hamilton E, Pathmanathan S, Greer B, Harriott P, Timson DJ (2011) IQ-motif selectivity in human IQGAP2 and IQGAP3: binding of calmodulin and myosin essential light chain. Biosci Rep 31:371–379. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Avruch J, Xavier R, Bardeesy N, Zhang XF, Praskova M, Zhou D, Xia F (2009) Rassf family of tumor suppressor polypeptides. J Biol Chem 284:11001–11005. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR (2012) Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol 23:770–784. CrossRefPubMedPubMedCentralGoogle Scholar
  13. Backer JM et al (1992) Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11:3469–3479CrossRefGoogle Scholar
  14. Banerjee A, Jang H, Nussinov R, Gaponenko V (2016) The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding. Curr Opin Struct Biol 36:10–17. CrossRefPubMedGoogle Scholar
  15. Barnoud T, Schmidt ML, Donninger H, Clark GJ (2017) The role of the NORE1A tumor suppressor in oncogene-induced senescence. Cancer Lett 400:30–36. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Boehr DD, Nussinov R, Wright PE (2009) The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 5:789–796. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J (1998) The structural basis of the activation of Ras by Sos. Nature 394:337–343. CrossRefPubMedGoogle Scholar
  18. Bruder JT, Heidecker G, Rapp UR (1992) Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev 6:545–556CrossRefGoogle Scholar
  19. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 alpha (PIK3CA). Proc Natl Acad Sci U S A 109:15259–15264. CrossRefPubMedPubMedCentralGoogle Scholar
  20. Castellano E, Downward J (2011) RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2:261–274. CrossRefPubMedPubMedCentralGoogle Scholar
  21. Chang LC et al (2014) Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterol 14(221).
  22. Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D (1993) Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260:1338–1343CrossRefGoogle Scholar
  23. Chaudhuri P, Rosenbaum MA, Sinharoy P, Damron DS, Birnbaumer L, Graham LM (2016) Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation. Proc Natl Acad Sci U S A 113:2110–2115. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Chavan TS et al (2015) High-affinity interaction of the K-Ras4B hypervariable region with the Ras active site. Biophys J 109:2602–2613. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Cherfils J, Chardin P (1999) GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 24:306–311CrossRefGoogle Scholar
  26. Cherfils J, Zeghouf M (2013) Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 93:269–309. CrossRefPubMedGoogle Scholar
  27. Choi BH, Chen C, Philips M, Dai W (2018) RAS GTPases are modified by SUMOylation. Oncotarget 9:4440–4450. CrossRefPubMedGoogle Scholar
  28. Choi S, Anderson RA (2016) IQGAP1 is a phosphoinositide effector and kinase scaffold. Adv Biol Regul 60:29–35. CrossRefPubMedGoogle Scholar
  29. Choi S, Hedman AC, Sayedyahossein S, Thapa N, Sacks DB, Anderson RA (2016) Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases. Nat Cell Biol 18:1324–1335. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Chong H, Guan KL (2003) Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 278:36269–36276. CrossRefPubMedGoogle Scholar
  31. Chong H, Lee J, Guan KL (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20:3716–3727. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Chuang E, Barnard D, Hettich L, Zhang XF, Avruch J, Marshall MS (1994) Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol 14:5318–5325CrossRefGoogle Scholar
  33. Cook SJ, McCormick F (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069–1072CrossRefGoogle Scholar
  34. Crews CM, Erikson RL (1993) Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 74:215–217CrossRefGoogle Scholar
  35. Cutler RE Jr, Stephens RM, Saracino MR, Morrison DK (1998) Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A 95:9214–9219CrossRefGoogle Scholar
  36. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15:322–331. CrossRefPubMedPubMedCentralGoogle Scholar
  37. del Sol A, Tsai CJ, Ma B, Nussinov R (2009) The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 17:1042–1050. CrossRefPubMedPubMedCentralGoogle Scholar
  38. Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W (2002a) Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21:64–71CrossRefGoogle Scholar
  39. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W (2002b) Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 22:3237–3246CrossRefGoogle Scholar
  40. Donninger H, Schmidt ML, Mezzanotte J, Barnoud T, Clark GJ (2016) Ras signaling through RASSF proteins. Semin Cell Dev Biol 58:86–95. CrossRefPubMedPubMedCentralGoogle Scholar
  41. Dumaz N, Marais R (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278:29819–29823. CrossRefPubMedGoogle Scholar
  42. Fallahi E, O’Driscoll NA, Matallanas D (2016) The MST/Hippo pathway and cell death: a non-canonical affair. Genes (Basel) 7:28. CrossRefGoogle Scholar
  43. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507–517CrossRefGoogle Scholar
  44. Fetics SK, Guterres H, Kearney BM, Buhrman G, Ma B, Nussinov R, Mattos C (2015) Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23:505–516. CrossRefPubMedGoogle Scholar
  45. Francis SH, Poteet-Smith C, Busch JL, Richie-Jannetta R, Corbin JD (2002) Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases. Front Biosci 7:d580–d592CrossRefGoogle Scholar
  46. Freedman TS, Sondermann H, Friedland GD, Kortemme T, Bar-Sagi D, Marqusee S, Kuriyan J (2006) A Ras-induced conformational switch in the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A 103:16692–16697. CrossRefPubMedPubMedCentralGoogle Scholar
  47. Freeman AK, Ritt DA, Morrison DK (2013) Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 49:751–758. CrossRefPubMedPubMedCentralGoogle Scholar
  48. Fukui M, Yamamoto T, Kawai S, Mitsunobu F, Toyoshima K (1987) Molecular cloning and characterization of an activated human c-raf-1 gene. Mol Cell Biol 7:1776–1781CrossRefGoogle Scholar
  49. Gabelli S et al (2014) Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev 6:89–95. CrossRefPubMedPubMedCentralGoogle Scholar
  50. Goldfinger LE, Michael JV (2017) Regulation of Ras signaling and function by plasma membrane microdomains. Biosci Trends 11:23–40. CrossRefPubMedGoogle Scholar
  51. Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, McCammon JA (2007) Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 50:674–684. CrossRefPubMedGoogle Scholar
  52. Gupta S et al (2007) Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129:957–968. CrossRefPubMedGoogle Scholar
  53. Gureasko J, Kuchment O, Makino DL, Sondermann H, Bar-Sagi D, Kuriyan J (2010) Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A 107:3430–3435. CrossRefPubMedPubMedCentralGoogle Scholar
  54. Hamad NM et al (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045–2057. CrossRefPubMedPubMedCentralGoogle Scholar
  55. Hatzivassiliou G et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431–435. CrossRefGoogle Scholar
  56. Hedman AC, Smith JM, Sacks DB (2015) The biology of IQGAP proteins: beyond the cytoskeleton. EMBO Rep 16:427–446. CrossRefPubMedPubMedCentralGoogle Scholar
  57. Heidecker G et al (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503–2512CrossRefGoogle Scholar
  58. Herrmann C, Horn G, Spaargaren M, Wittinghofer A (1996) Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem 271:6794–6800CrossRefGoogle Scholar
  59. Herrmann C, Martin GA, Wittinghofer A (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 270:2901–2905CrossRefGoogle Scholar
  60. Hu J et al (2013) Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154:1036–1046. CrossRefPubMedGoogle Scholar
  61. Huang CH et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318:1744–1748. CrossRefPubMedGoogle Scholar
  62. Hwang E et al (2014) Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the hippo signalling pathway. Acta Crystallogr D Biol Crystallogr 70:1944–1953. CrossRefPubMedPubMedCentralGoogle Scholar
  63. Improta-Brears T, Ghosh S, Bell RM (1999) Mutational analysis of Raf-1 cysteine rich domain: requirement for a cluster of basic aminoacids for interaction with phosphatidylserine. Mol Cell Biochem 198:171–178CrossRefGoogle Scholar
  64. Ishikawa F, Sakai R, Ochiai M, Takaku F, Sugimura T, Nagao M (1988) Identification of a transforming activity suppressing sequence in the c-raf oncogene. Oncogene 3:653–658PubMedGoogle Scholar
  65. Ishikawa F, Takaku F, Hayashi K, Nagao M, Sugimura T (1986) Activation of rat c-raf during transfection of hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A 83:3209–3212CrossRefGoogle Scholar
  66. Iwasa H, Hossain S, Hata Y (2018) Tumor suppressor C-RASSF proteins. Cell Mol Life Sci 75:1773–1787. CrossRefPubMedGoogle Scholar
  67. Jambrina PG, Bohuszewicz O, Buchete NV, Kolch W, Rosta E (2014) Molecular mechanisms of asymmetric RAF dimer activation. Biochem Soc Trans 42:784–790. CrossRefPubMedGoogle Scholar
  68. Jambrina PG et al (2016) Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation. Angew Chem Int Ed Engl 55:983–986. CrossRefPubMedGoogle Scholar
  69. Jang H et al (2015) Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem 290:9465–9477. CrossRefPubMedPubMedCentralGoogle Scholar
  70. Jang H, Banerjee A, Chavan T, Gaponenko V, Nussinov R (2017) Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction. J Biol Chem 292:12544–12559. CrossRefPubMedPubMedCentralGoogle Scholar
  71. Jang H, Banerjee A, Chavan TS, Lu S, Zhang J, Gaponenko V, Nussinov R (2016) The higher level of complexity of K-Ras4B activation at the membrane. FASEB J 30:1643–1655. CrossRefPubMedGoogle Scholar
  72. Jarvis LM (2011) Pi3k at the clinical crossroads. Chemical & Engineering News 89:15–19Google Scholar
  73. Jaumot M, Hancock JF (2001) Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20:3949–3958. CrossRefPubMedGoogle Scholar
  74. Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M (2017) RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat Commun 8(1211).
  75. Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB (1997) Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem 272:28183–28186CrossRefGoogle Scholar
  76. Joyal JL, Crimmins DL, Thoma RS, Sacks DB (1996) Identification of insulin-stimulated phosphorylation sites on calmodulin. Biochemistry 35:6267–6275. CrossRefPubMedGoogle Scholar
  77. Karasarides M, Anand-Apte B, Wolfman A (2001) A direct interaction between oncogenic ha-Ras and phosphatidylinositol 3-kinase is not required for Ha-Ras-dependent transformation of epithelial cells. J Biol Chem 276:39755–39764. CrossRefPubMedGoogle Scholar
  78. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK (2000) Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404:151–158. CrossRefPubMedGoogle Scholar
  79. Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ (1994) The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 4:798–806CrossRefGoogle Scholar
  80. Kohler M et al (2016) Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J 35:143–161. CrossRefPubMedGoogle Scholar
  81. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R (2000) Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 9:10–19. CrossRefPubMedPubMedCentralGoogle Scholar
  82. Lavoie H et al (2018) MEK drives BRAF activation through allosteric control of KSR proteins. Nature 554:549–553. CrossRefPubMedGoogle Scholar
  83. Lavoie H, Therrien M (2015) Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 16:281–298. CrossRefPubMedGoogle Scholar
  84. Lavoie H et al (2013) Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 9:428–436. CrossRefPubMedPubMedCentralGoogle Scholar
  85. Lepri F et al (2011) SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat 32:760–772. CrossRefPubMedPubMedCentralGoogle Scholar
  86. Li S, Jang H, Zhang J, Nussinov R (2018a) Raf-1 cysteine-rich domain increases the affinity of K-Ras/Raf at the membrane, promoting MAPK signaling. Structure 26:513–525. CrossRefPubMedGoogle Scholar
  87. Li Z, Sacks DB (2003) Elucidation of the interaction of calmodulin with the IQ motifs of IQGAP1. J Biol Chem 278:4347–4352. CrossRefPubMedGoogle Scholar
  88. Li ZL, Buck M (2017) Computational modeling reveals that signaling lipids modulate the orientation of K-Ras4A at the membrane reflecting protein topology. Structure 25:679–689 e672. CrossRefPubMedPubMedCentralGoogle Scholar
  89. Li ZL, Prakash P, Buck M (2018b) A “tug of war” maintains a dynamic protein-membrane complex: molecular dynamics simulations of C-Raf RBD-CRD bound to K-Ras4B at an anionic membrane. ACS Cent Sci 4:298–305. CrossRefPubMedPubMedCentralGoogle Scholar
  90. Liao J, Planchon SM, Wolfman JC, Wolfman A (2006) Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J Biol Chem 281:29730–29738. CrossRefPubMedGoogle Scholar
  91. Liao TJ, Jang H, Fushman D, Nussinov R (2018) Allosteric KRas4B can modulate SOS1 fast and slow Ras activation cycles. Biophys J. CrossRefGoogle Scholar
  92. Liao TJ, Jang H, Tsai CJ, Fushman D, Nussinov R (2017) The dynamic mechanism of RASSF5 and MST kinase activation by Ras. Phys Chem Chem Phys 19:6470–6480. CrossRefPubMedPubMedCentralGoogle Scholar
  93. Liao TJ, Tsai CJ, Jang H, Fushman D, Nussinov R (2016) RASSF5: an MST activator and tumor suppressor in vivo but opposite in vitro. Curr Opin Struct Biol 41:217–224. CrossRefPubMedGoogle Scholar
  94. Light Y, Paterson H, Marais R (2002) 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 22:4984–4996CrossRefGoogle Scholar
  95. Linnemann T, Kiel C, Herter P, Herrmann C (2002) The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution. J Biol Chem 277:7831–7837. CrossRefPubMedGoogle Scholar
  96. Liu J, Nussinov R (2016) Allostery: an overview of its history, concepts, methods, and applications. PLoS Comput Biol 12:e1004966. CrossRefPubMedPubMedCentralGoogle Scholar
  97. Liu J, Nussinov R (2017) Energetic redistribution in allostery to execute protein function. Proc Natl Acad Sci U S A 114:7480–7482. CrossRefPubMedPubMedCentralGoogle Scholar
  98. Lommerse PH, Snaar-Jagalska BE, Spaink HP, Schmidt T (2005) Single-molecule diffusion measurements of H-Ras at the plasma membrane of live cells reveal microdomain localization upon activation. J Cell Sci 118:1799–1809. CrossRefPubMedGoogle Scholar
  99. Ma B, Kumar S, Tsai CJ, Nussinov R (1999) Folding funnels and binding mechanisms. Protein Eng 12:713–720CrossRefGoogle Scholar
  100. Ma B, Tsai CJ, Haliloglu T, Nussinov R (2011) Dynamic allostery: linkers are not merely flexible. Structure 19:907–917. CrossRefPubMedGoogle Scholar
  101. Makbul C, Constantinescu Aruxandei D, Hofmann E, Schwarz D, Wolf E, Herrmann C (2013) Structural and thermodynamic characterization of Nore1-SARAH: a small, helical module important in signal transduction networks. Biochemistry 52:1045–1054. CrossRefPubMedGoogle Scholar
  102. Mandelker D et al (2009) A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc Natl Acad Sci U S A 106:16996–17001. CrossRefPubMedPubMedCentralGoogle Scholar
  103. Margarit SM et al (2003) Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112:685–695CrossRefGoogle Scholar
  104. Martins AJ et al (2017) Environment tunes propagation of cell-to-cell variation in the human macrophage gene network. Cell Syst 4 e312:379–392. CrossRefGoogle Scholar
  105. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18:2137–2148. CrossRefPubMedPubMedCentralGoogle Scholar
  106. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232–260. CrossRefPubMedPubMedCentralGoogle Scholar
  107. Mazhab-Jafari MT et al (2015) Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proc Natl Acad Sci U S A 112:6625–6630. CrossRefPubMedPubMedCentralGoogle Scholar
  108. Michael JV, Wurtzel JG, Goldfinger LE (2016) Inhibition of Galectin-1 sensitizes HRAS-driven tumor growth to rapamycin treatment. Anticancer Res 36:5053–5061. CrossRefPubMedGoogle Scholar
  109. Michaud NR, Fabian JR, Mathes KD, Morrison DK (1995) 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner. Mol Cell Biol 15:3390–3397CrossRefGoogle Scholar
  110. Miled N et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239–242. CrossRefPubMedGoogle Scholar
  111. Molders H, Defesche J, Muller D, Bonner TI, Rapp UR, Muller R (1985) Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion. EMBO J 4:693–698CrossRefGoogle Scholar
  112. Molzan M, Ottmann C (2012) Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3zeta dimer. J Mol Biol 423:486–495. CrossRefPubMedGoogle Scholar
  113. Morrison DK, Heidecker G, Rapp UR, Copeland TD (1993) Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 268:17309–17316PubMedGoogle Scholar
  114. Mott HR, Carpenter JW, Zhong S, Ghosh S, Bell RM, Campbell SL (1996) The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Proc Natl Acad Sci U S A 93:8312–8317CrossRefGoogle Scholar
  115. Muslin AJ, Tanner JW, Allen PM, Shaw AS (1996) Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84:889–897CrossRefGoogle Scholar
  116. Nakhaeizadeh H, Amin E, Nakhaei-Rad S, Dvorsky R, Ahmadian MR (2016) The RAS-effector Interface: isoform-specific differences in the effector binding regions. PLoS One 11:e0167145. CrossRefPubMedPubMedCentralGoogle Scholar
  117. Nussinov R (2016) Introduction to protein ensembles and allostery. Chem Rev 116:6263–6266. CrossRefPubMedGoogle Scholar
  118. Nussinov R, Jang H, Tsai CJ, Liao TJ, Li S, Fushman D, Zhang J (2017a) Intrinsic protein disorder in oncogenic KRAS signaling. Cell Mol Life Sci 74:3245–3261. CrossRefPubMedGoogle Scholar
  119. Nussinov R, Ma B, Tsai CJ (2013a) A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta 1834:820–829. CrossRefPubMedGoogle Scholar
  120. Nussinov R, Ma B, Tsai CJ, Csermely P (2013b) Allosteric conformational barcodes direct signaling in the cell. Structure 21:1509–1521. CrossRefPubMedGoogle Scholar
  121. Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O (2015a) The key role of calmodulin in KRAS-driven adenocarcinomas. Mol Cancer Res 13:1265–1273. CrossRefPubMedPubMedCentralGoogle Scholar
  122. Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O (2016a) K-Ras4B/calmodulin/PI3Kalpha: a promising new adenocarcinoma-specific drug target? Expert Opin Ther Targets 20:831–842. CrossRefPubMedGoogle Scholar
  123. Nussinov R, Tsai CJ (2015) ‘Latent drivers’ expand the cancer mutational landscape. Curr Opin Struct Biol 32:25–32. CrossRefPubMedGoogle Scholar
  124. Nussinov R, Tsai CJ, Csermely P (2011) Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacol Sci 32:686–693. CrossRefPubMedGoogle Scholar
  125. Nussinov R, Tsai CJ, Jang H (2016b) Independent and core pathways in oncogenic KRAS signaling. Expert Rev Proteomics 13:711–716. CrossRefPubMedPubMedCentralGoogle Scholar
  126. Nussinov R, Tsai CJ, Jang H (2018a) Is nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant? Semin Cancer Biol:DOI.
  127. Nussinov R, Tsai CJ, Jang H (2018b) Oncogenic KRas mobility in the membrane and signaling response. Semin Cancer Biol.
  128. Nussinov R, Tsai CJ, Jang H (2018c) Oncogenic Ras isoforms signaling specificity at the membrane. Cancer Res 78:593–602. CrossRefPubMedGoogle Scholar
  129. Nussinov R, Tsai CJ, Jang H, Korcsmaros T, Csermely P (2016c) Oncogenic KRAS signaling and YAP1/beta-catenin: similar cell cycle control in tumor initiation. Semin Cell Dev Biol 58:79–85. CrossRefPubMedGoogle Scholar
  130. Nussinov R, Tsai CJ, Ma B (2013c) The underappreciated role of allostery in the cellular network. Annu Rev Biophys 42:169–189. CrossRefPubMedGoogle Scholar
  131. Nussinov R, Tsai CJ, Muratcioglu S, Jang H, Gursoy A, Keskin O (2015b) Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation. Expert Rev Proteomics 12:669–682. CrossRefPubMedGoogle Scholar
  132. Nussinov R, Tsai CJ, Xin F, Radivojac P (2012) Allosteric post-translational modification codes. Trends Biochem Sci 37:447–455. CrossRefPubMedGoogle Scholar
  133. Nussinov R et al (2017b) Calmodulin and PI3K signaling in KRAS cancers. Trends Cancer 3:214–224. CrossRefPubMedPubMedCentralGoogle Scholar
  134. Nussinov R, Wolynes PG (2014) A second molecular biology revolution? The energy landscapes of biomolecular function. Phys Chem Chem Phys 16:6321–6322. CrossRefPubMedGoogle Scholar
  135. Nussinov R, Zhang M, Tsai CJ, Jang H (2018d) Calmodulin and IQGAP1 activation of PI3Kalpha and Akt in KRAS, HRAS and NRAS-driven cancers. Biochim Biophys Acta 1864:2304–2314. CrossRefGoogle Scholar
  136. Ory S, Zhou M, Conrads TP, Veenstra TD, Morrison DK (2003) Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 13:1356–1364CrossRefGoogle Scholar
  137. Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book:DOI.
  138. Ozdemir ES, Jang H, Gursoy A, Keskin O, Li Z, Sacks DB, Nussinov R (2018) Unraveling the molecular mechanism of interactions of the Rho GTPases Cdc42 and Rac1 with the scaffolding protein IQGAP2. J Biol Chem 293:3685–3699. CrossRefPubMedGoogle Scholar
  139. Pacold ME et al (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103:931–943CrossRefGoogle Scholar
  140. Panchal SC, Kaiser DA, Torres E, Pollard TD, Rosen MK (2003) A conserved amphipathic helix in WASP/Scar proteins is essential for activation of Arp2/3 complex. Nat Struct Biol 10:591–598. CrossRefPubMedGoogle Scholar
  141. Peterson JR, Bickford LC, Morgan D, Kim AS, Ouerfelli O, Kirschner MW, Rosen MK (2004) Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation. Nat Struct Mol Biol 11:747–755. CrossRefPubMedGoogle Scholar
  142. Peterson JR, Golemis EA (2004) Autoinhibited proteins as promising drug targets. J Cell Biochem 93:68–73. CrossRefPubMedGoogle Scholar
  143. Pierre S, Bats AS, Coumoul X (2011) Understanding SOS (Son of Sevenless). Biochem Pharmacol 82:1049–1056. CrossRefPubMedGoogle Scholar
  144. Pons-Tostivint E, Thibault B, Guillermet-Guibert J (2017) Targeting PI3K signaling in combination cancer therapy. Trends Cancer 3:454–469. CrossRefPubMedGoogle Scholar
  145. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430. CrossRefPubMedPubMedCentralGoogle Scholar
  146. Rabinovich GA (2005) Galectin-1 as a potential cancer target. Br J Cancer 92:1188–1192. CrossRefPubMedPubMedCentralGoogle Scholar
  147. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M (2009) A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542–545. CrossRefPubMedGoogle Scholar
  148. Ren JG, Li Z, Sacks DB (2008) IQGAP1 integrates Ca2+/calmodulin and B-Raf signaling. J Biol Chem 283:22972–22982. CrossRefPubMedPubMedCentralGoogle Scholar
  149. Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114–128. CrossRefPubMedGoogle Scholar
  150. Rodriguez-Viciana P, Sabatier C, McCormick F (2004) Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24:4943–4954. CrossRefPubMedPubMedCentralGoogle Scholar
  151. Rodriguez-Viciana P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467CrossRefGoogle Scholar
  152. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442–2451CrossRefGoogle Scholar
  153. Rojas JM, Oliva JL, Santos E (2011) Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes Cancer 2:298–305. CrossRefPubMedPubMedCentralGoogle Scholar
  154. Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN, Kolch W (2014) Protein interaction switches coordinate Raf-1 and MST2/hippo signalling. Nat Cell Biol 16:673–684. CrossRefPubMedGoogle Scholar
  155. Rommel C et al (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286:1738–1741CrossRefGoogle Scholar
  156. Rommel C et al (1996) Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12:609–619PubMedGoogle Scholar
  157. Rotblat B et al (2010) H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 5:e11991. CrossRefPubMedPubMedCentralGoogle Scholar
  158. Rusanescu G, Gotoh T, Tian X, Feig LA (2001) Regulation of Ras signaling specificity by protein kinase C. Mol Cell Biol 21:2650–2658. CrossRefPubMedPubMedCentralGoogle Scholar
  159. Sanchez-Sanz G et al (2016) SARAH domain-mediated MST2-RASSF dimeric interactions. PLoS Comput Biol 12:e1005051. CrossRefPubMedPubMedCentralGoogle Scholar
  160. Schlessinger J (2003) Signal transduction. Autoinhibition control. Science 300:750–752. CrossRefPubMedGoogle Scholar
  161. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308. CrossRefPubMedGoogle Scholar
  162. Schultz AM, Copeland T, Oroszlan S, Rapp UR (1988) Identification and characterization of c-raf phosphoproteins in transformed murine cells. Oncogene 2:187–193PubMedGoogle Scholar
  163. Simicek M et al (2013) The deubiquitylase USP33 discriminates between RALB functions in autophagy and innate immune response. Nat Cell Biol 15:1220–1230. CrossRefPubMedGoogle Scholar
  164. Smith JM, Hedman AC, Sacks DB (2015) IQGAPs choreograph cellular signaling from the membrane to the nucleus. Trends Cell Biol 25:171–184. CrossRefPubMedPubMedCentralGoogle Scholar
  165. Stanishneva-Konovalova TB, Kelley CF, Eskin TL, Messelaar EM, Wasserman SA, Sokolova OS, Rodal AA (2016) Coordinated autoinhibition of F-BAR domain membrane binding and WASp activation by nervous wreck. Proc Natl Acad Sci U S A 113:E5552–E5561. CrossRefPubMedPubMedCentralGoogle Scholar
  166. Stanton VP Jr, Cooper GM (1987) Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 7:1171–1179CrossRefGoogle Scholar
  167. Stanton VP Jr, Nichols DW, Laudano AP, Cooper GM (1989) Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol 9:639–647CrossRefGoogle Scholar
  168. Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5:357–365. CrossRefPubMedGoogle Scholar
  169. Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, Herrmann C (2008) Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 27:1995–2005. CrossRefPubMedPubMedCentralGoogle Scholar
  170. Sydor JR, Engelhard M, Wittinghofer A, Goody RS, Herrmann C (1998) Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. Biochemistry 37:14292–14299. CrossRefPubMedGoogle Scholar
  171. Tartaglia M et al (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75–79. CrossRefPubMedGoogle Scholar
  172. Terrell EM, Morrison DK (2018) Ras-mediated activation of the Raf family kinases. Cold Spring Harb Perspect Med.
  173. Thapar R, Williams JG, Campbell SL (2004) NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J Mol Biol 343:1391–1408. CrossRefPubMedGoogle Scholar
  174. Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F, Therrien M (2015) Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol 22:37–43. CrossRefPubMedGoogle Scholar
  175. Tran NH, Frost JA (2003) Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 278:11221–11226. CrossRefPubMedGoogle Scholar
  176. Tran NH, Wu X, Frost JA (2005) B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 280:16244–16253. CrossRefPubMedGoogle Scholar
  177. Travers T, Lopez CA, Van QN, Neale C, Tonelli M, Stephen AG, Gnanakaran S (2018) Molecular recognition of RAS/RAF complex at the membrane: role of RAF cysteine-rich domain. Sci Rep 8(8461).
  178. Tsai CJ, Del Sol A, Nussinov R (2009) Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol BioSyst 5:207–216. CrossRefPubMedPubMedCentralGoogle Scholar
  179. Tsai CJ, Kumar S, Ma B, Nussinov R (1999a) Folding funnels, binding funnels, and protein function. Protein Sci 8:1181–1190. CrossRefPubMedPubMedCentralGoogle Scholar
  180. Tsai CJ, Ma B, Nussinov R (1999b) Folding and binding cascades: shifts in energy landscapes. Proc Natl Acad Sci U S A 96:9970–9972CrossRefGoogle Scholar
  181. Tsai CJ, Nussinov R (2014a) The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Phys Chem Chem Phys 16:6332–6341. CrossRefPubMedGoogle Scholar
  182. Tsai CJ, Nussinov R (2014b) A unified view of “how allostery works”. PLoS Comput Biol 10:e1003394. CrossRefPubMedPubMedCentralGoogle Scholar
  183. Tu H, Wigler M (1999) Genetic evidence for Pak1 autoinhibition and its release by Cdc42. Mol Cell Biol 19:602–611CrossRefGoogle Scholar
  184. Tzivion G, Luo Z, Avruch J (1998) A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394:88–92. CrossRefPubMedGoogle Scholar
  185. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 4:re2. CrossRefPubMedGoogle Scholar
  186. Vandal G, Geiling B, Dankort D (2014) Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. PLoS One 9:e84745. CrossRefPubMedPubMedCentralGoogle Scholar
  187. Vanhaesebroeck B et al (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535–602. CrossRefPubMedGoogle Scholar
  188. Villalonga P et al (2001) Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol 21:7345–7354. CrossRefPubMedPubMedCentralGoogle Scholar
  189. Vo U, Vajpai N, Flavell L, Bobby R, Breeze AL, Embrey KJ, Golovanov AP (2016) Monitoring Ras interactions with the nucleotide exchange factor Son of Sevenless (Sos) using site-specific NMR reporter signals and intrinsic fluorescence. J Biol Chem 291:1703–1718. CrossRefPubMedGoogle Scholar
  190. Wan L et al (2017) The APC/C E3 ligase complex activator FZR1 restricts BRAF oncogenic function. Cancer Discov 7:424–441. CrossRefPubMedPubMedCentralGoogle Scholar
  191. Wan PT et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867CrossRefGoogle Scholar
  192. Wang G et al (2018) Interaction of calmodulin with the cSH2 domain of the p85 regulatory subunit. Biochemistry 57:1917–1928. CrossRefPubMedGoogle Scholar
  193. Wei G, Xi W, Nussinov R, Ma B (2016) Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell. Chem Rev 116:6516–6551. CrossRefPubMedGoogle Scholar
  194. Weise K et al (2011) Membrane-mediated induction and sorting of K-Ras microdomain signaling platforms. J Am Chem Soc 133:880–887. CrossRefPubMedGoogle Scholar
  195. White CD, Brown MD, Sacks DB (2009) IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 583:1817–1824. CrossRefPubMedPubMedCentralGoogle Scholar
  196. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW (1993) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262:1065–1069CrossRefGoogle Scholar
  197. Xu Y, Li N, Xiang R, Sun P (2014) Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci 39:268–276. CrossRefPubMedPubMedCentralGoogle Scholar
  198. Zhang BH, Guan KL (2000) Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19:5429–5439. CrossRefPubMedPubMedCentralGoogle Scholar
  199. Zhang BH, Guan KL (2001) Regulation of the Raf kinase by phosphorylation. Exp Lung Res 27:269–295CrossRefGoogle Scholar
  200. Zhang C et al (2015) RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526:583–586. CrossRefPubMedGoogle Scholar
  201. Zhang L et al (2018a) Ras and Rap signal bidirectional synaptic plasticity via distinct subcellular microdomains. Neuron 98 e784:783–800. CrossRefGoogle Scholar
  202. Zhang M, Jang H, Gaponenko V, Nussinov R (2017) Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains. Biophys J 113:1956–1967. CrossRefPubMedPubMedCentralGoogle Scholar
  203. Zhang M et al (2018b) Calmodulin (CaM) activates PI3Kalpha by targeting the “soft” CaM-binding motifs in both the nSH2 and cSH2 domains of p85alpha. J Phys Chem B.
  204. Zhao L, Vogt PK (2008a) Class IPI3K in oncogenic cellular transformation. Oncogene 27:5486–5496. CrossRefPubMedPubMedCentralGoogle Scholar
  205. Zhao L, Vogt PK (2008b) Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 105:2652–2657. CrossRefPubMedPubMedCentralGoogle Scholar
  206. Zhao L, Vogt PK (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9:596–600. CrossRefPubMedPubMedCentralGoogle Scholar
  207. Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741–1744CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchNational Cancer Institute at FrederickFrederickUSA
  2. 2.Department of Human Molecular Genetics and Biochemistry, Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Biophysics Program, Institute for Physical Science and TechnologyUniversity of MarylandCollege ParkUSA
  4. 4.Department of Chemistry and Biochemistry, Center for Biomolecular Structure and OrganizationUniversity of MarylandCollege ParkUSA

Personalised recommendations